$KNSA Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.33 up 37.50% YoY
• Reported revenue of $243.6M up 55.36% YoY
• Kiniksa Pharmaceuticals expects 2026 ARCALYST net product revenue to be between $980 million and $995 million, raised from prior guidance of between $930 million and $945 million for the fiscal year.